{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:24:39Z","timestamp":1771017879572,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,8,10]],"date-time":"2007-08-10T00:00:00Z","timestamp":1186704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:p>A new lung\u2010targeting and controlled releasing preparation, enrofloxacin microsphere, was formulated and its physical properties, stability, pharmacokinetics and lung\u2010targeting characteristics were tested in this study. The enrofloxacin microsphere prepared was demonstrated round and regular, which was easy to be dispersed and stable in both light stability test and heat stability test. Following intravenous administration of a single dose in dog, the drug concentration\u2013time data in the lung were fitted most suitably with three\u2010compartment open model. Compared with enrofloxacin injection (Baytril<jats:sup>\u00ae<\/jats:sup>), half\u2010life of distribution phase in the lung was shortened from 0.72 to 0.16\u2003h, half\u2010life of elimination phase in the lung was prolonged from 5.15 to 33.86\u2003h and clearance of drug concentration in the lung was decreased from 0.603 to 0.267\u2003L\/h\/kg. Lung\u2010targeting parameters, including the relative intake rate (<jats:italic>R<\/jats:italic><jats:sub>e<\/jats:sub>), targeting efficacy (<jats:italic>T<\/jats:italic><jats:sub>e<\/jats:sub>) and the ratio of peak concentration (<jats:italic>C<\/jats:italic><jats:sub>e<\/jats:sub>), were calculated according to the pharmacokinetic parameters. The results showed that<jats:italic>R<\/jats:italic><jats:sub>e<\/jats:sub>(2.48) and<jats:italic>C<\/jats:italic><jats:sub>e<\/jats:sub>(4.27) of the lung was much greater than that of other tissues and the ratio of<jats:italic>T<\/jats:italic><jats:sub>e(microsphere)<\/jats:sub>to<jats:italic>T<\/jats:italic><jats:sub>e(Baytril<\/jats:sub><jats:sup>\u00ae<\/jats:sup>) increased by a factor of 1.77 (compared with liver) to 3.51 (compared with spleen). Therefore, the enrofloxacin microsphere prepared in this study had controlled releasing and lung\u2010targeting effects in dog.<\/jats:p>","DOI":"10.1111\/j.1365-2885.2007.00895.x","type":"journal-article","created":{"date-parts":[[2007,8,11]],"date-time":"2007-08-11T06:26:09Z","timestamp":1186813569000},"page":"443-450","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetics and lung\u2010targeting characterization of a newly formulated enrofloxacin preparation"],"prefix":"10.1111","volume":"30","author":[{"given":"S.","family":"TANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"XIAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/AAC.43.4.954","article-title":"Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis","volume":"43","author":"Bebear C.M.","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.2.433-438.2001"},{"key":"e_1_2_6_4_1","first-page":"744","article-title":"Enrofloxacin revisited","volume":"8","author":"Boothe D.M.","year":"1994","journal-title":"Veterinary Medicine"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061504"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1996.tb00001.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1756"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2581-2584.2000"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2460\/ajvr.1995.56.03.386","article-title":"Enrofloxacin concentrations in dogs with normal prostate and dogs with chronic bacterial prostatitis","volume":"56","author":"Dorfman M.","year":"1995","journal-title":"American Journal of Veterinary Research"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg269"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1135(02)00087-1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-4017(02)00325-4"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(89)90018-5"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.2037"},{"key":"e_1_2_6_15_1","first-page":"242","article-title":"The targeting of drugs parenterally by use of microspheres","volume":"36","author":"Illum L.","year":"1982","journal-title":"Journal Parenteral Science and Technology"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(82)90113-2"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005773603905"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2005.11.004"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2460\/javma.1998.212.02.200","article-title":"Role of Bordetella bronchiseptica in infectious tracheobronchitis in dogs","volume":"212","author":"Keil D.J.","year":"1998","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1993.tb00212.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(03)00138-3"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(96)02033-X"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(03)00332-6"},{"key":"e_1_2_6_24_1","first-page":"375","article-title":"Clarithromycin targeting to lung: optimization of the size, morphology and release characteristics of albumin microspheres","volume":"57","author":"Ozkan Y.","year":"2000","journal-title":"Acta Poloniae Pharmaceutica"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-827X(00)00044-6"},{"key":"e_1_2_6_26_1","first-page":"195","article-title":"In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin","volume":"54","author":"Prescott J.F.","year":"1990","journal-title":"Canadian Journal of Veterinary Research"},{"key":"e_1_2_6_27_1","first-page":"122","article-title":"Enrofloxacin: a new antimicrobial agent","volume":"60","author":"Schroder J.","year":"1989","journal-title":"Journal of the South African Veterinary Association"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9797(89)90013-1"},{"key":"e_1_2_6_29_1","first-page":"173","article-title":"The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity","volume":"80","author":"Vancutsem P.M.","year":"1990","journal-title":"The Cornell Veterinarian"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1135(00)00221-2"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01117450"},{"key":"e_1_2_6_32_1","first-page":"188","volume-title":"Chinese Veterinary Pharmacopoeia","author":"Zhang Y.","year":"2000"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/321841"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1086\/338571"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2885.2007.00895.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2885.2007.00895.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T10:09:58Z","timestamp":1708164598000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2885.2007.00895.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1365-2885.2007.00895.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2885.2007.00895.x","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,10]]}}}